There is a brief, heartbreaking window in the life of a boy with Duchenne muscular dystrophy when the disease is already doing damage — yet no one can see it yet.

Muscle destruction in DMD begins at birth. But the weakness, the delayed milestones, the diagnosis — those typically don't arrive until the early school years. By then, researchers at Binghamton University say, the damage is already well underway.

Now a new clinical study suggests that treating boys much earlier — before age 4, before most families even know their child has the condition — could make a significant and measurable difference.

A drug already approved

The treatment in question is Vamorolone (brand name: Agamree), an anti-inflammatory drug developed by Binghamton researchers Eric Hoffman and Raju Nagaraju and approved by the FDA in 2023 specifically for DMD. It was designed to provide the benefits of traditional corticosteroids — which slow muscle deterioration — while reducing their most troublesome side effects, including stunted growth and weight gain.

Because Vamorolone has an improved growth-safety profile compared to conventional steroids, the team was able to ask a question that had previously seemed too risky: What happens if we start treatment even earlier?

Jaw-dropping results in 12 weeks

The Phase II open-label study enrolled 20 boys between the ages of 2 and 4 who had never previously received steroids. Participants received either 2 or 6 milligrams of Vamorolone per kilogram of body weight each day for 12 weeks, with most continuing for roughly two years through an expanded-access program.

The results surprised even the researchers.

"We were surprised at the rapid improvement of gross motor skills," said Professor Hoffman.

On the Bayley III gross-motor scale, healthy children of that age typically score around 10. The boys with DMD began the study at approximately 5 — half the healthy benchmark. After just 12 weeks of treatment, their average score had climbed to around 8.

For children with a disease defined by progressive muscle loss, that kind of gain in such a short window is remarkable. The higher-dose group showed particularly striking improvement.

There were no serious adverse events during the 12-week period. Some children experienced weight gain and adrenal suppression, particularly at the higher dose, and researchers emphasize that the study was small with no placebo control — so it is not a definitive clinical trial. But the signal is strong enough to warrant much larger follow-up studies.

Why early treatment matters so much

For decades, standard DMD treatment protocols waited until symptoms were obvious. That approach, Hoffman explains, meant intervening only after the destructive process had already been running — silently — for years.

"The destructive processes in muscle start from birth," he said, even though symptoms typically aren't recognized until children enter school. By then, significant scar tissue may have already replaced healthy muscle that can never be restored.

Starting treatment before that window closes could, in theory, preserve muscle that would otherwise be lost.

Newborn screening opens a new door

The timing of this research couldn't be better. Duchenne muscular dystrophy was recently added to the U.S. Recommended Uniform Screening Panel for newborns. That means more boys will now be identified at or near birth — long before symptoms appear and long before traditional intervention timelines.

"Hopefully, Vamorolone may become an option for these babies if these preliminary data are confirmed," Hoffman said.

That vision — of catching DMD at birth and treating it before a single stride is lost — represents a genuine shift in how this disease might one day be managed. The disease affects approximately 1 in every 3,500 newborn males, making it one of the most common fatal genetic conditions in the world.

The results were published in the journal Neurology, and the researchers have begun planning the next phase of trials.